

In the Abstract of the Disclosure:

Please amend the Abstract of the Disclosure as indicated below. A "Version With Marking to Show Changes Made to the Specification and the Abstract of the Disclosure" is presented in Appendix A.

Please replace the title of the Application with the following:

D2 METHODS FOR INHIBITING THE INTERACTION OF B7-2 WITH ITS NATURAL LIGAND

Please replace the Abstract of the Disclosure with the following paragraph:

D3 The present invention relates to, inter alia, methods for inhibiting the interaction of the B-lymphocyte antigen, B7-2, with its natural ligand on the surface of an immune cell are disclosed. The methods comprise contacting the immune cell with an agent which inhibits B7-2 binding with its natural ligand, to thereby inhibit the interaction. Examples of such agents are provided, and include a soluble form of B7-2, an antibody that recognized B7-2. The method may also include contacting the immune cell with an agent that blocks the interaction of B7-1 with its natural ligand. Further, the method may include contacting the immune cell with an immunomodulating agent, for example, an antibody reactive with CD28, an antibody reactive with CTLA4, an antibody reactive with a cytokine, a CTLA4Ig fusion protein, a CD28Ig fusion protein, and an immunosuppressive drug. Both *in vivo* and *in vitro* applications of the method are disclosed.

In the Claims:

— / — ✓ ✓  
Please cancel non-elected claims 63-64 and 68-69 without prejudice.